Highlights of the 2013 Annual Meeting will be discussions on advanced strategies for targeted immunotherapies. Dedicated sessions on the tumor micro-environment and on combination therapies will talk about disease mechanisms and address the optimization of immunotherapies:
Who can benefit, when and why?
Exciting recent results on combining immunotherapies with other standard cancer treatments are presented through preclinical and clinical data. Sessions in therapeutic vaccination, cellular therapy and improving immunity will discuss recent advances and future applications. In addition, CIP (CIMT Immunoguding Program) and CIMT-RRG (Regulatory Research Group) will hold sessions and panel discussions focusing on standardized and innovative tools for improving the quality of immunomonitoring and facilitating the translation of scientific knowledge to drug development.
May 13, 2013 – 11:30-16:00
A new satellite workshop focusing on the translation and commercialization of cancer immunotherapies and diagnostics.
The registration fee of 50 EUR includes lunch, snacks and drinks. A registration discount of 20 EUR applies to participants already registered for CIMT.
For more information and registration click here:
![]()
S. van der Burg
(Leiden University Medical Center, Leiden)
A. Hoos
(CRI-CIC, Glaxo Smith Kline, Collegeville)
M. Theobald
(3rd Medical Department, University Medical Center Mainz)
U. Kalinke
(Twincore, Hannover)
D. Schendel
(Institute for Molecular Immunology, Helmholtz Center, Munich)
S. Kreiter
(CIMT Executive Director Science; Institute for Translational Oncology, Mainz)
M. Diken
(CIMT Scientific Secretary, Institute for Translational Oncology , Mainz)
W. Herr
(3rd Medical Department, University Medical Center Mainz)
C. Britten
(CIMT Executive Director Translational Medicine, 3rd Medical Department, University Medical Center Mainz)
H. J. Schild
(Institute for Immunology, University Medical Center Mainz)
R. Kiessling
(Karolinska Institutet, Stockholm)
C. Gouttefangeas
(University of Tübingen)